Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study in healthy male and female adult participants. The study will include up to 48 participants (12 participants per cohort) who will be randomized 9:3 to active drug or placebo. Each cohort will receive AZD4041 or placebo in a MAD study. A sequential cohort MAD design will be employed to assure that higher doses are administered to healthy participants only after lower doses have demonstrated an acceptable safety profile. The total study duration will be up to 59 days (including Screening) per participant.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05233085
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1
Start date December 17, 2021
Completion date June 7, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04111939 - HEALing Communities Study N/A
Withdrawn NCT03547882 - Addiction Treatment in Primary Care Expansion
Recruiting NCT04464980 - Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) Phase 2
Recruiting NCT05209334 - A Safety Study of AZD4041 in Healthy Volunteers Phase 1